All News

ild.jpg

Risk Factors for Rheumatoid Arthritis-associated Interstitial Lung Disease

d Jack Cush, MD

Sparks and colleagues have published a matched cohort analysis demonstrating risk factors that may augment the risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), especially the combination of obesity, high CRP, high MD-HAQ and >30 pack-year smoking h

Read Article
NSAIDs.pills_.caps_.jpg

NSAID Safety with COVID-19 Infection

d Jack Cush, MD

NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.

Read Article
cost.price_.biologic.injectable.jpg

Insurers Bet Big on Bribing Patients

d Madelaine Feldman, MD, and Jay Salliotte

Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

AURORA-1: Voclosporin Efficacy in Lupus Nephritis

d Jack Cush, MD

Lancet has published the results of the AURORA-1 trial, wherein the calcineurin inhibitor, voclosporin, was tested in a placebo controlled trial of lupus nephritis and shown to be effective at inducing a complete renal response.

Read Article
FDA.jpg (keep)

FDA Advisors Split on Avacopan for Vasculitis

d MedPage Today

Members of an FDA advisory panel were sharply divided as to whether avacopan, an oral small molecule inhibitor of the C5a receptor, was sufficiently safe and effective for treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Read Article
blood, level, numbers, data, calculation

Higher Hydroxychloroquine Blood Levels Reduces Thrombosis Risk in Lupus

d Jack Cush, MD

Petri and colleagues have published that measuring hydroxychloroquine (HCQ) blood levels can be useful in systemic lupus erythematosus (SLE), as low levels are associated with an increased thrombotic risk in SLE.

Read Article
Dr. Janet Pope - Comorbidities in SLE From ACR 2019 https://t.co/1BjfVOfL4i https://t.co/CRqUKeYUmi

Links:

Dr. John Cush RheumNow ( View Tweet)
5 Reasons to see Rheumatologist 1. Unexplained, worsening joint or muscle pains 2. Repeated, joint pain/swelling, fevers, rashes 3. Establish early Dx to your chronic joint complaints 4. Review abnormal labs, get a treatment plan 5. Attacks of gout https://t.co/gRVtnM4i7J

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Kathryn Dao - Lupus Pearls from ACR 2019 https://t.co/JDlfjAO0xe #LupusAwarenessMonth https://t.co/1ZiZiNvYhv

Links:

Dr. John Cush RheumNow ( View Tweet)
It's #LupusAwarenessMonth --review our lupus coverage from the archives. Dr. Janet Pope - New SLE criteria and guidelines and approach to refractory Lupus patients From RWCS 2020 https://t.co/eufxObGFic https://t.co/pReB8aPHlp

Links:

Dr. John Cush RheumNow ( View Tweet)
Bandaid counts in Scleroderma? Scleroderma skin scoring w/ Modified Rodnan Skin Score. But how to serially assess digital ulcers ? I do a Digital Ulcer count (open + healing) and a "Bandaid Score" - Pts use bandaids to tell you how many are problematic https://t.co/NEWC6e8ttb
Dr. John Cush RheumNow ( View Tweet)
News Feature: Higher Hydroxychloroquine Blood Levels Reduces Thrombosis Risk in Lupus Petri and colleagues have published that measuring HCQ blood levels is useful in SLE patients as low levels are associated with thrombosis in SLE. https://t.co/jAXUJoM2Pa https://t.co/h8KonZRnX8

Links:

Dr. John Cush RheumNow ( View Tweet)
A retrospective cohort study of 419 gout patients compared low dose 0.6 mg qd (LD) vs regular 0.6 mg bid (RD) colchicine as prophylaxis when starting urate lowering therapy. Rate of gout flares were roughly equal (LD 14.3% vs RD 11.3%) https://t.co/8G6siQlHbI

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Childhood Lupus May Hamper Adult Careers Long-term outcomes of kids with cSLE are uncommon, but this cSLE cohort analysis suggests that SLE significantly impacts their future education, vocation, and employment as they reach adulthood. https://t.co/RQc4JD3BIt https://t.co/y5LboAUsw3

Links:

Dr. John Cush RheumNow ( View Tweet)
281,264 people vax w/ Oxford-AstraZeneca COVID vaccine - had 59 VTEs (30 expected; 2 fold incr.) +Higher than expected cerebral VTE seen (excess of 2.5 100K Vax). Thrombocytopenia/coagulation disorders were rare but not in excess. https://t.co/m3cjqkzHSW

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review of the epidemiology of #RA shows average point and period prevalence of RA to be 51 to 56 per 10,000, respectively. Higher with rheumatologist diagnosis (81 per 10,000). https://t.co/5AeNdmBLJO

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Unique Oral Microbiome in Early and Pre-Clinical RA An oral microbiome study of rheumatoid arthritis (RA) patients suggests that periodontal condition in patients with early rheumatoid arthritis (ERA) and individuals at risk of RA. https://t.co/r3kT52MByC https://t.co/MocZ6PXZzA

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you listened to the latest RheumNow podcast? Falling or Falling in Love https://t.co/SmPCqKpXLY https://t.co/LQSsGJCY9u

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Avacopan for ANCA Vasculitis Goes in Front of the FDA An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for ANCA-associated vasculitis. https://t.co/66NSjbkE8Q https://t.co/9cR2lBASjz

Links:

Dr. John Cush RheumNow ( View Tweet)
#LupusAwarenessMonth Dr. Kathryn Dao - Risk of Hydroxychloroquine Retinal Toxicity From ACR 2020 https://t.co/7BCVvMOm0T https://t.co/PhHubO7rxG

Links:

Dr. John Cush RheumNow ( View Tweet)
×